The global Preimplantation Genetic Testing Market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.
High
adoption of In Vitro Fertilization (IVF) technique consequently upsurges the
utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are
advantageous in a way that they allow the development of a healthy fetus and
prevent the risk of selective pregnancy termination. Hence, PGT acts as an
addendum to assisted reproductive technology.
A
substantial number of patients with infertility and impaired fecundity are
recommended to embrace IVF therapy in combination with PGT procedures, which in
turn is expected to stimulate the growth. In addition, public and private
authorities are promoting reproductive health by undertaking initiatives is
also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD)
market.
Related Press Release@ Preimplantation Genetic Testing Market
Preimplantation Genetic Testing Market Report Highlights
·
Availability of a significant number of services related
to early diagnosis of specific gene mutation in embryo marked the dominant
position of PGD in 2018
·
Preimplantation Genetic Screening (PGS) seems to be
reasonable intervention to enhance efficiency of selecting chromosomally normal
embryo during IVF cycles. It is increasingly being applied for embryo screening
due to ever-expanding IVF, which is projected to create lucrative growth
opportunities in near future
- Advancements
in detection of chromosomal anomalies by executing non-invasive prenatal
testing results in a maximum share of this segment in 2018
- Expanding
utilization rate of FISH probe sets and benefits associated with the
detection of a single-gene disorder is expected to fuel the growth of
X-linked diseases segment
- Implementation
of PGT in embryo HLA typing for stem cell therapy is expected to impose
segment growth. This is further attributed to the advantages pertaining to
PGS testing for identification of HLA compatible embryos during stem cell
therapy
- Europe
accounts for largest revenue share in 2018 owing to increased usage of PGD
and PGS for the delivery of genetically healthy offspring during IVF
procedures
- Asia Pacific
market is observed to reveal the fastest CAGR due to the rise in medical
tourism and the continuous development of IVF and PGD clinics in Asian
countries
- Key players
that have commercialized PGT services include
Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina,
Inc.; IGENOMIX; and others
- Key
participants are actively involved in expansion of the distribution
network for their products as well as R&D activities for the
development of novel PGT services. In October 2018, Illumina Inc. signed
an agreement with Vitrolife AB under which Vitrolife act as a distributor
supplier of Illumina’s PGT products in EMEA and America.
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment